Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

CIS001 Extension Study of Cyclosporine Inhalation Solution

Study:

CIS002: An Open-Label, Multi-Center, Extension Study of Cyclosporine Inhalation Solution in Subjects Previously Enrolled in the APT Study CIS001

Rationale:

n/a

Purpose:

This trial is a longterm follow up of a phase III study of inhaled cyclosporine for the prevention of chronic rejection in lung transplant recipients.

Study Status: Terminated

Recruiting:
n/a

Condition Intervention Phase
Lung Transplant Drug: Cyclosporine Inhalation Solution (CIS) Phase 3

Verified by APT Pharmaceuticals, Inc. September, 2012

Sponsored by: APT Pharmaceuticals, Inc.
Information provided by: APT Pharmaceuticals, Inc.
ClinicalTrials.gov identifier: NCT00938236

Study Type: Interventional

Study Design: Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention

Cleveland Clinic
Cleveland, Ohio 44195
United States

Bruce A Johnson, MD., Principal Investigator
Jeffrey Golden, MD., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site